TDOC Stock — Teladoc Health, Inc.

Up next

Next earnings call

Oct 29, 2026 Est · unconfirmed · in 6 wks

Latest filing: 10-Q

filed Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$2.49B

Trailing 12 months

Net income (TTM)

−$177.40M

Trailing 12 months

Revenue growth YoY

-4.0%

Year over year

Operating margin

-7.5%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

20.9%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.9%

Year over year · more shares

Price change (1Y)

-18.3%

Trailing year

Short interest

13.9%

Latest settlement · 7.2 days to cover

View all 115 metrics

Equibles Research

our published analysis of this company

Research Thesis July 19, 2026

Hims & Hers has 26.4% shorts arguing against $2.9B of guided 2026 revenue; the Q2 print decides whether subscriber growth or ARPU decay wins

Hims & Hers closed at $32.84, off 50.4% from its 52-week high, with short interest at 26.4% of shares outstanding and the steepest positioning in the comp set against a +59.0% TTM revenue base and a 10%–12% full-year adjusted EBITDA guide — the next quarter decides whether the multiple re-rates with subscriber growth or compresses further on the 6% ARPU slide.

Mentioned in fund letters

Lakeside Advisors, INC. Jan 4, 2022

FOURTH QUARTER MARKET REVIEW

Greenhaven Road Capital Jan 1, 2022

Open investor letter

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 15.4 · calm Equity put/call 0.52

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −6%

below

Price vs 50-day avg −15%

below

RSI (14) 43

neutral

MACD trend Positive

52-week position 34%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −6%

trailing

6-month return +14%

trailing

YTD return −10%

this year

Relative strength −4%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $7 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+7% holders QoQ · +64 funds added

Insider flow Distributing

Net -$365.0K over 90 days · 100% sells

Short interest Rising

13.95% of float · ▲ +7.0% MoM · 7.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

355 holders — mid 3-yr range

Squeeze score 67

elevated · 0–100

Fundamentals

Excellent

Revenue growth +18%

Y/Y

Gross margin 12%

expanding

EPS growth +81%

Y/Y

Free cash flow $285.5M

Balance sheet $5.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 64%

annualized · 1-yr

Max drawdown −53%

past year

ATR 4.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 6 of last 8

Latest guidance · from the 8-K filed Jul 29, 2026

Full Year 2026

Revenue Initiated $2.36B – $2.45B

prior FY $2.53B midpoint −5.0% Y/Y

Adjusted EBITDA Non-GAAP Initiated $271M – $303M

Integrated Care Revenue growth percentage (year-over-year) Initiated 0.8% – 2.4%

Free Cash Flow Non-GAAP Initiated $130M – $170M

Integrated Care Adjusted EBITDA margin Non-GAAP Initiated 15.6% – 16.4%

BetterHelp Adjusted EBITDA margin Non-GAAP Initiated 3% – 4.6%

3Q 2026

Revenue Initiated $569M – $609M

prior qtr $606.93M midpoint −3.0% QoQ

BetterHelp Adjusted EBITDA margin Non-GAAP Initiated 0.5% – 2.5%

Adjusted EBITDA Non-GAAP Initiated $62M – $74M

Prior guidance period ended · from the 8-K filed Jul 31, 2024

Adjusted EBITDA margin · For the third quarter of 2024 14.5% – 16%

Guided vs delivered · last 8 settled

Revenue 2Q 2024

guided $635M – $660M

guided $635M – $660M $642.44M In line

Revenue Full Year 2024

guided $2.64B – $2.74B

guided $2.64B – $2.74B $2.57B Miss −4.3%

Revenue full year 2021

guided $2.02B – $2.03B

guided $2.02B – $2.03B $2.03B Beat +0.6%

Revenue fourth quarter of 2021

guided $536M – $546M

guided $536M – $546M $554.24M Beat +2.4%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−6% Bearish

Price vs 50-day avg

−15% Bearish

RSI (14)

43 Neutral

MACD trend

Positive Bullish

52-week position

34% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $7 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+7% holders QoQ · +64 funds added

Insider flow Distributing

Net -$365.0K over 90 days · 100% sells

Short interest Rising

13.95% of float · ▲ +7.0% MoM · 7.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

355 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $4 Now $6 · 34% Range high $10

vs 200-day avg -6% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Health Information Services — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
TDOC Teladoc Health, Inc. this stock	$1.21B	-10.3%	+18.4%	—	13.9%
VEEV Veeva Systems Inc	$43.69B	+18.2%	+28.1%	44.2	3.0%
PMDIY Pro Medicus Ltd./ADR	$12.54B	-28.9%	—	—	0.0%
TEM Tempus AI, Inc.	$11.99B	+36.1%	+83.4%	—	16.3%
BTSG BrightSpring Health Services, Inc.	$11.73B	+51.1%	+28.2%	35.9	5.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

355

% held: 89.5%
Net QoQ: +10.3M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

259

View

Short & Settlement

Short Interest Rising

Shares short

25.3M

Days to cover: 7.2d
Change: +1.7M sh

View

Short Volume

Short vol %

72%

As of: Sep 17, 2026

Short Total

View

Fails to Deliver

FTD shares

261

Value: $1.7K
As of: Aug 27, 2026

View

Off-Exchange

Off-exchange %

37.8%

Week of: Aug 10, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$365.0K

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Congressional Trades Sell

Member

Donald Sternoff Beyer

Amount: $1.0K–$15.0K
Traded: Nov 26, 2021

View

Financials

Revenue (FY)

$2.5B

Net income (FY): $-200.3M
EPS diluted: $-1.14

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 31, 2026
This year: 15

View

Proposed Sales

Value

$108.7K

Shares: 17.8K
Filed: Sep 11, 2026

View

Exempt Offerings

Offering

$834.0M

Filed: Jul 10, 2020

View

Earnings & Events

Earnings Calls

Last call

Jul 29, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
TDOC	+3.1%	-5.7%	+13.8%	-1.0%	-10.3%
SPY	+0.6%	-0.8%	+18.2%	-0.6%	+11.8%
vs SPY	+2.5%	-4.9%	-4.5%	-0.4%	-22.1%

TDOC · Teladoc Health, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Research

Mentioned in fund letters

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance